Salsaga Blog

XI’AN, China, March 31 /Xinhua-PRNewswire-FirstCall/ — Huifeng Bio- Pharmaceutical Technology, Inc. (BULLETIN BOARD: HFGB) , a developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, is pleased to announce its audited financial results for the year ended December 31, 2007.Full Year 2007 Highlights:The following is a summary of our financial results for the full year ended Dec. 31, 2007. 12 Months Ended 12 Months Ended Growth In US Dollars December 31,2007 December 31,2006 ACIORFIPROCENTE Net Revenue $6,571,531 $3,076,779 114ACIORFIPROCENTE Gross Profit $1,977,313 $457,518 332ACIORFIPROCENTE Gross Profit Margin 30ACIORFIPROCENTE 15ACIORFIPROCENTE Net Income $1,283,683 $131,736 874ACIORFIPROCENTE Net Income Margin 20ACIORFIPROCENTE 4ACIORFIPROCENTE Earnings Per Share $0.07 $0.01 600ACIORFIPROCENTEHuifeng achieved outstanding growth during 2007, with sales more than doubling and net income increasing by over 800ACIORFIPROCENTE. “Huifeng achieved a number of significant milestones in 2007. We have increased our product offering and achieved significant sales in both Rutin and Diosmin,” states company CEO Jing’An Wang. Furthermore, in late 2007, Huifeng signed the largest supply agreement in company history and completed a $2 million fundraising.”Huifeng expects to continue achieving significant gains in both sales and net income in 2008 through organic growth of our current products,” forecasted Mr. Wang. The company restructured its production lines in the fourth quarter to accommodate the increased production levels of Diosmin necessitated under its current contract with Safic-Alcan of France. Huifeng also hopes to close a strategic acquisition in 2008 under its stated policy of seeking synergistic, accretive acquisitions in the Xi’an region of China.The company is maintaining its stated guidance of sales of US$18 million and net income of US$4 million ($0.18 cents per share) in 2008.For more detailed information on this transaction, investors should refer to Huifeng’s Current Report on Form 10-KSB and related exhibits filed with the Securities and Exchange Commission on Friday, March 31, 2008.This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi’an, People’s Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, included or incorporated by reference herein relating to management’s current expectations of future financial performance, continued growth, changes in economic conditions or capital markets and our ability to consummate strategic acquisitions are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.Words or phrases such as “anticipates,”"may,”"will,”"should,”"believes,”"estimates,”"expects,”"intends,”"plans,”"hopes,”"predicts,”"projects,”"targets,”"will likely result,”"will continue” or similar expressions identify forward-looking statements. Forward-looking statements involve risks and uncertainties which could cause actual results or outcomes to differ materially from those expressed. We caution that while we make such statements in good faith and believe such statements are based on reasonable assumptions, including without limitation, management’s examination of historical operating trends, data contained in records and other data available from third parties, we cannot assure you that our projections will be achieved. For more information, please contact: Dan Carlson, Primary Capital LLC Email: Huifeng Bio-Pharmaceutical Technology, Inc.

Filed under: Biotechonology by admin - No Comments →

PALO ALTO, Calif., March 31 /PRNewswire-FirstCall/ — Varian, Inc. (NasdaqGS: VARI) announced today the release of the VF-5ht UltiMetal(TM) column for high temperature gas chromatography (GC), which is resistant to damage under extreme operating conditions. These highly durable columns allow chemists to confidently analyze samples at very high temperatures, up to 450 degrees Celsius. Based on a stainless steel capillary, Varian’s UltiMetal columns address several problems associated with fused silica columns. A proprietary manufacturing process renders the steel inert and enhances the bonding of the stationary phase. The result is long column lifetime with excellent peak shape and low column bleed for the best detection limits at high temperatures. The UltiMetal column is a high performance, lasting solution for high temperature gas chromatography.The columns have wide applicability in the separation of high boiling mixtures such as long chain hydrocarbons, polymers, plastics, waxes, heavy polyaromatic hydrocarbons, tars, triglycerides, motor oils, surfactants and crown ethers.The VF-5ht UltiMetal column is the latest addition to Varian’s superb FactorFour range of low bleed GC columns. FactorFour columns offer bleed specifications up to four times better than alternative products. The columns are synthesized using a proprietary stabilization technology that results in high signal-to-noise ratios for trace analysis, lower detector contamination for reduced maintenance, better spectra, fewer background ions and faster stabilization. In short, they provide better chromatography.”Less column breakage results in savings for laboratories that analyze samples with high temperature GC,” says Martin O’Donoghue, Senior Vice President, Scientific Instruments, Varian, Inc. “Higher temperatures are often applied to speed up the analysis of high boiling components and boost productivity. The VF-5ht UltiMetal column is the ideal solution for these applications.”For more technical information about Varian’s GC and Mass Spectrometry instrumentation and consumables, please visit Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 3,900 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2007 sales of $921 million, and its common stock is traded on the NASDAQ Global Select Market under the symbol, “VARI.” Further information is available on the company’s Web site: . For More Information, Contact: Public Relations Varian, Inc. 650.424.3845Varian, Inc.

Filed under: Biotechonology by admin - No Comments →